-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Industry Analysts Just Made A Sizeable Upgrade To Their Kindstar Globalgene Technology, Inc. (HKG:9960) Revenue Forecasts
Industry Analysts Just Made A Sizeable Upgrade To Their Kindstar Globalgene Technology, Inc. (HKG:9960) Revenue Forecasts
Shareholders in Kindstar Globalgene Technology, Inc. (HKG:9960) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The revenue forecast for this year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.
Following the upgrade, the current consensus from Kindstar Globalgene Technology's two analysts is for revenues of CN¥1.2b in 2022 which - if met - would reflect a reasonable 3.3% increase on its sales over the past 12 months. Statutory earnings per share are supposed to sink 13% to CN¥0.097 in the same period. Prior to this update, the analysts had been forecasting revenues of CN¥1.1b and earnings per share (EPS) of CN¥0.087 in 2022. There has definitely been an improvement in perception recently, with the analysts substantially increasing both their earnings and revenue estimates.
Check out our latest analysis for Kindstar Globalgene Technology
SEHK:9960 Earnings and Revenue Growth August 17th 2022Although the analysts have upgraded their earnings estimates, there was no change to the consensus price target of CN¥3.03, suggesting that the forecast performance does not have a long term impact on the company's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Kindstar Globalgene Technology at CN¥3.70 per share, while the most bearish prices it at CN¥3.30. This is a very narrow spread of estimates, implying either that Kindstar Globalgene Technology is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Kindstar Globalgene Technology's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Kindstar Globalgene Technology's revenue growth will slow down substantially, with revenues to the end of 2022 expected to display 3.3% growth on an annualised basis. This is compared to a historical growth rate of 28% over the past year. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 19% annually. Factoring in the forecast slowdown in growth, it seems obvious that Kindstar Globalgene Technology is also expected to grow slower than other industry participants.
The Bottom Line
The most important thing to take away from this upgrade is that analysts upgraded their earnings per share estimates for this year, expecting improving business conditions. Pleasantly, analysts also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow slower than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Kindstar Globalgene Technology.
Analysts are definitely bullish on Kindstar Globalgene Technology, but no company is perfect. Indeed, you should know that there are several potential concerns to be aware of, including concerns around earnings quality. For more information, you can click through to our platform to learn more about this and the 1 other warning sign we've identified .
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
股東在Kindstar全球基因科技公司(HKG:9960)獲悉分析師剛剛對其近期預測作出重大上調,可能會感到興奮。今年的營收預測發生了翻天覆地的變化,分析師們現在對其銷售渠道的看法要樂觀得多。
升級後,Kindstar Globalgene Technology的兩位分析師目前的共識是,2022年收入將達到人民幣12億元,如果實現這一目標,將比過去12個月的銷售額合理增長3.3%。同期法定每股收益預計將下降13%,至人民幣0.097元。在此次更新之前,分析師一直預測2022年收入為11億加元,每股收益為0.087加元。最近人們的看法肯定有所改善,分析師大幅提高了他們的收益和收入預期。
查看我們對Kindstar Globalgene Technology的最新分析
聯交所:9,960盈利及收入增長2022年8月17日儘管分析師上調了盈利預期,但CN元3.03元的一致目標價沒有變化,這表明預測業績不會對公司估值產生長期影響。共識價格目標只是個別分析師目標的平均值,因此-看看基礎估計的範圍有多大可能很方便。目前,最樂觀的分析師對Kindstar Globalgene Technology的估值為每股3.70元人民幣,而最悲觀的分析師估值為3.30元人民幣。這是一個非常窄的估計價差,這意味着要麼Kindstar Globalgene Technology是一家很容易估值的公司,要麼--更有可能的是--分析師嚴重依賴一些關鍵假設。
這些估計很有趣,但當看到預測如何與Kindstar Globalgene Technology過去的表現和同行業同行進行比較時,描繪一些更寬泛的筆觸可能會很有用。很明顯,人們預計Kindstar Globalgene Technology的收入增長將大幅放緩,截至2022年底的收入預計將按年率計算增長3.3%。相比之下,過去一年的歷史增長率為28%。與該行業的其他公司(與分析師的預測)相比,這些公司的總收入預計將以每年19%的速度增長。考慮到增長放緩的預期,Kindstar Globalgene Technology的增長速度預計也將低於其他行業參與者,這似乎是顯而易見的。
底線
此次上調最重要的一點是,分析師上調了對今年每股收益的預期,預計商業狀況會有所改善。令人高興的是,分析師還上調了他們的收入預期,他們的預測表明,該業務的增長速度預計將低於整體市場。鑑於分析師似乎預計銷售渠道將大幅改善,現在可能是重新審視Kindstar Globalgene Technology的合適時機。
分析師絕對看好Kindstar Globalgene Technology,但沒有一家公司是完美的。事實上,你應該知道有幾個潛在的擔憂需要注意,包括對收益質量的擔憂。欲瞭解更多信息,您可以點擊我們的平臺,瞭解更多關於這一點和我們確定的其他1個警告信號的信息。
當然,看到公司管理層投資大筆資金投資一隻股票,就像知道分析師是否在上調他們的預期一樣有用。所以你可能也想搜索一下這個免費內部人士正在買入的股票清單。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧